Wednesday, December 19, 2012 8:43:28 PM
VVUS-Shares of Vivus (VVUS) are active in the post session on speculation that Johnson & Johnson (JNJ) and AstraZeneca (AZN) are considering a takeover of the drug developer due to the company's obesity drug Qsymia. Pfizer (PFE) may also take an interest should VVUS come under takeover attack, because obestity drugs are a hot item at present - with over 78M obese adults in the U.S. alone. Deal-watchers are skeptical however, noting that any deal with a chance of success would need to be in the $30-plus per share range. VVUS +1.3% AH.
Manny
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM